No Detail Found!

Bempedoic acid and ezetimibe combination therapy in patients with high cardiovascular disease risk: A narrative review of current research

Author(s)
Herwindo Ahmad Division of Cardiovascular, Department of Internal Medicine, Faculty of Medicine,Universitas Sumatera Utara,Indonesia
Darmadi Darmadi Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Indonesia
Maggie Liberty Faculty of Medicine, Universitas Sumatera Utara, Indonesia
Abstract
Objective: To provide a comprehensive overview of bempedoic acid and ezetimibe combination therapy, including its mechanism of action, recent evidence on its benefits and safety, and future potential as a new cardioprotective therapy, particularly in high CVD risk patients. Methodology: Literature search was performed on 3 search engines: PubMed/MEDLINE, ScienceDirect, and Cochrane Library. The included studies were assessed for the quality of study methods and reported data. Data were synthesized narratively, summarizing and discussing various research findings of combination therapy. Conclusion: Bempedoic acid and ezetimibe combination therapy had a potential advantage in reducing CVD risk. Several simulation studies predicted that the cardioprotective effects of bempedoic acid and ezetimibe FDC therapy would advance the monotherapies.
Publication Details
Page(s) 216-221
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 50, Issue: 1, Year: 2025

Request the full text from PASTIC

Keywords
hypercholesterolemia, Cardiovascular diseases., Ezetimibe, LDLcholesterol, bempedoic acid
References
Mach F,Baigent C,Catapano AL,Koskinas KC,Casula M,Badimon L .2020 .ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 41 : 111-88.
Libby P,Buring JE,Badimon L,Hansson GK,Deanfield J,Bittencourt MS .2019 .. Nat Rev Dis Primers, 5 : 56-9.
Ference BA,Ginsberg HN,Graham I,Ray KK,Packard CJ,Bruckert E .2017 .Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 38 : 2459-72.
Arnett DK,Blumenthal RS,Albert MA,Buroker AB,Goldberger ZD,Hahn EJ .2019 .ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 10 : 140.
Ferrieres J,Gorcyca K,Lorga SR .2018 .Lipid lowering therapy and goal achievement in high-risk patients from French general practice. Clin Ther, 40 : 1484-95.
Vrablík M,Šarkanová I,Breciková K,Šedová P,Šatný M,Tichopád A .2023 .Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias. PLoS One, 18 : e0272883.
Ruscica M,Banach M,Sahebkar A,Corsini A,Sirtori CR .2019 .Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opin Pharmacother, 20 : 791-803.
Ballantyne CM,Laufs U,Ray KK,Leiter LA,Bays HE,Goldberg AC .2019 .Bempedoic acid plus ezetimibe fixeddose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol, 27 : 593-603.
Sterne JAC,Savović J,Page MJ,Elbers RG,Blencowe NS,Boutron I .2019 .RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 10 : l4898.
Sterne JAC,Hernán MA,Reeves BC,Savović J,Berkman ND,Viswanathan M .2016 .ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ, 10 : i4919.
Laufs U,Ballantyne CM,Banach M,Bays H,Catapano AL,Duell PB .2022 .Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol, 16 : 286-97.
Bays HE,Baum SJ,Brinton EA,Plutzky J,Hanselman JC,Teng R .2021 .Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on lowdensity lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. Am J Prev Cardiol, 8 : 100278.
Migliaccio-Walle K,Elsea D,Gupta A,Sarnes E,Griffith K,Pandey R .2024 .Treatment intensification with bempedoic acid to achieve LDL-C goal in patients with ASCVD: A simulation model using a real-world patient cohort in the US. Atheroscler Plus, 55 : 98-105.
McQueen RB,Baum SJ,Louie MJ,Sasiela WJ,Bilitou A,Shah H .2023 .Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins. Am J Cardiovasc Drugs, 23 : 67-76.
Amore BM,Cramer C,MacDougall D,Emery MG .2023 .The Disposition and Metabolism of Bempedoic Acid, a Potent Inhibitor of ATP Citrate Lyase. Drug Metab Dispos, 51 : 599-609.
Sizar O,Nassereddin A,Talati R.,Ezetimibe R.,Available R. . .StatPearls Publishing; 2024 Jan-. , : .
Ferri N,Ruscica M,Santos RD,Corsini A .2023 .Fixed Combination for the Treatment of Dyslipidaemia. Curr Atheroscler Rep, 25 : 691-699.
Borén J,Chapman MJ,Krauss RM,Packard CJ,Bentzon JF,Binder CJ .2020 .Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 41 : 2313-30.
Sabatine MS,Giugliano RP,Keech AC,Honarpour N,Wiviott SD,Murphy SA .2017 .Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 376 : 1713-1722.
Goldberg AC,Leiter LA,Stroes ESG,Baum SJ,Hanselman JC,Bloedon LT .2019 .Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA, 322 : 1780-8.
Jadhav SB,Crass RL,Chapel S,Kerschnitzki M,Sasiela WJ,Emery MG .2022 .Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. Eur Heart J Cardiovasc Pharmacother, 8 : 578-586.
Oyama K,Giugliano RP,Blazing MA,Park JG,Tershakovec AM,Sabatine MS .2021 .Baseline lowdensity lipoprotein cholesterol and clinical outcomes of combining ezetimibe with statin therapy in IMPROVE-IT. J Am Coll Cardiol, 78 : 1499-1507.
Kim BK,Hong SJ,Lee YJ,Hong SJ,Yun KH,Hong BK .2022 .Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus highintensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet, 400 : 380-390.
Sabatine MS,Giugliano RP,Keech AC,Honarpour N,Wiviott SD,Murphy SA .2017 .Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 376 : 1713-22.
Koren MJ,Sabatine MS,Giugliano RP,Langslet G,Wiviott SD,Kassahun H .2017 .Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years from the Open-Label OSLER-1 Extension Study. JAMA Cardiol, 2 : 598-607.
Bhagavathula AS,Al Matrooshi NO,Clark CCT,Rahmani J. Bempedoic,Acid J. Bempedoic .2021 .Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and MetaAnalysis of Randomized Phase II/III trials. Clin Drug Investig, 41 : 19-28.
0

Citations

0

Downloads

53

Views